Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System.

Publication Year: 2023

DOI:
10.1093/ofid/ofad552

PMCID:
PMC10644828

PMID:
38023539

Journal Information

Full Title: Open Forum Infect Dis

Abbreviation: Open Forum Infect Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Potential conflicts of interest. All authors had access to prescribe tecovirimat based on the CDC EA-IND protocol and local IRB approval. L. L. and G. P. are co-investigators on STOMP, and J. A. is the site principal investigator for the STOMP trial at the Icahn School of Medicine at Mount Sinai. All other authors report no potential conflicts."

Evidence found in paper:

"Financial support. No funding was available or used for this study. Financial support."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025